Latest Nkarta News & Updates

See the latest news and media coverage for Nkarta. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Nkarta

Clinical-stage biotechnology company developing therapies for autoimmune diseases

nkartatx.com
Headquarters
South San Francisco, United States
Founded year
2015
Company type
Public company
Number of employees
160–200

Last updated

Latest news about Nkarta

In short: Nkarta presented initial autoimmune trial data and reported FDA-agreed outpatient dosing changes

Company announcements

Nkarta

Nkarta posts Q1 2026 loss, cash runway to 2029

Cash and investments totaled $266.7 million; R&D expenses were $25.0 million and G&A $5.9 million.

Unlock all announcements with a

Media coverage

Yahoo Finance

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient...

Unlock all articles with a

Never miss news about Nkarta

Track Nkarta and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.